Read about our latest publication in the European Journal of Cancer, detailing the Phase I trial of TLD-1, a new liposomal doxorubicin formulation for advanced solid tumors. This study focuses on the methodical dose escalation and expansion within a multicenter, open-label setting. Discover the trial's findings and implications for patient care in the SAKK 65/16 trial under https://www.ejcancer.com/article/S0959-8049(24)00064-9/pdf .